bioLytical on-board with HIV strategy that could significantly reduce prevalence
bioLytical(TM) laboratories intends to partner with Dr. Julio Montaner, Director of the BC Center for Excellence in HIV/AIDS with the development and implementation of a new HIV strategy unveiled recently to help reduce the transmission rate of HIV.
"A key element of Dr. Montaner's strategy is to identify those infected with HIV and don't know it through a massive increase in point of care testing for the virus. We manufacture INSTI under very strict standards right here in British Columbia. Our product is fully approved by Health Canada for HIV point of care testing, and is available for use as soon as a strategic program is implemented. bioLytical Laboratories is committed to the control of this virus, and supports the research and initiatives of Dr. Montaner on all levels," says Matthew Clayton, Chief Operating Officer for bioLytical Laboratories.
INSTI is positioned to be an integral part of Dr. Montaner's prevention strategy. The availability for point of care HIV testing can serve as the starting point for the immediate entry of individuals into a treatment program aimed at reducing transmission of HIV. Rapid testing, along with the new highly effective one-pill-a-day, fixed-dose, drug combination represents a unique opportunity to expand local and global HAART (Highly Active Anti-Retroviral Therapy) programs and potentially control and reduce the global growth pandemic.
According to BioLytical, INSTI(TM) is a highly effective and reliable rapid HIV test that detects the presence of antibodies to HIV in whole blood, serum or plasma in 60 seconds. It has a 99.96% accuracy rate, as demonstrated in one of the most extensive clinical trials ever conducted.
Most read news
Organizations
Other news from the department research and development
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
![Topic world Antibodies](http://static.chemie.de//media/images/focuspage/022d2694-7e7f-411e-9219-c2cf6ea89d36.png)
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous